- Home
- NLSP vs CLRB Comparison
NLSP vs CLRB Comparison
Compare NLSP & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- CLRB
- Stock Information
- Founded
- NLSP 2015
- CLRB 2002
- Country
- NLSP Switzerland
- CLRB United States
- Employees
- NLSP N/A
- CLRB N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- CLRB Health Care
- Exchange
- NLSP Nasdaq
- CLRB Nasdaq
- Market Cap
- NLSP 12.4M
- CLRB 14.2M
- IPO Year
- NLSP 2021
- CLRB N/A
- Fundamental
- Price
- NLSP $2.07
- CLRB $4.82
- Analyst Decision
- NLSP
- CLRB Hold
- Analyst Count
- NLSP 0
- CLRB 2
- Target Price
- NLSP N/A
- CLRB N/A
- AVG Volume (30 Days)
- NLSP 179.9K
- CLRB 150.7K
- Earning Date
- NLSP 10-17-2025
- CLRB 08-14-2025
- Dividend Yield
- NLSP N/A
- CLRB N/A
- EPS Growth
- NLSP N/A
- CLRB N/A
- EPS
- NLSP N/A
- CLRB N/A
- Revenue
- NLSP N/A
- CLRB N/A
- Revenue This Year
- NLSP N/A
- CLRB N/A
- Revenue Next Year
- NLSP N/A
- CLRB N/A
- P/E Ratio
- NLSP N/A
- CLRB N/A
- Revenue Growth
- NLSP N/A
- CLRB N/A
- 52 Week Low
- NLSP $1.30
- CLRB $4.11
- 52 Week High
- NLSP $6.97
- CLRB $67.50
- Technical
- Relative Strength Index (RSI)
- NLSP 42.25
- CLRB 48.13
- Support Level
- NLSP $2.03
- CLRB $4.43
- Resistance Level
- NLSP $2.29
- CLRB $5.30
- Average True Range (ATR)
- NLSP 0.18
- CLRB 0.41
- MACD
- NLSP -0.06
- CLRB 0.11
- Stochastic Oscillator
- NLSP 3.88
- CLRB 59.66
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.